Oncology News | pharmaphorum

News

AZ, Daiichi Sankyo cue up TROP2 drug filing in breast cancer

Armed with the first phase 3 data for their TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan as a second-line treatment for breast cancer, AstraZeneca

News

Cancer Research UK earmarks £123m for Scottish R&D

Cancer Research UK (CRUK) has said it will award £123 million ($150 million) in funding over the next seven years to Scotland’s Beatson Institute, which will be renamed th

News

Menarini brings oral SERD to Europe with Orserdu okay

Menarini has secured EU approval for Orserdu, the first in a new class of oral selective oestrogen receptor degrader (SERD) drugs and the first innovation in endocrine the

News

Roche inks pipeline deals with Orionis, PeptiDream

Roche has bolstered its R&D pipeline in oncology and neuroscience with a pair of partnerships with Orionis Biosciences and PeptiDream, parting with upfront cash of $87

News

Merck puts $1.3bn into AI via Exscientia, BenevolentAI deals

German group Merck has revved up its artificial intelligence-powered drug discovery with partnerships with two UK companies – Exscientia and BenevolentAI – that will focus

News

Novartis returns PD-1 antibody rights to BeiGene

BeiGene confirmed today that Novartis has pulled out of a partnership on PD-1 inhibitor tislelizumab, two and half years after paying $650 million upfront for ex-China rig

AZ, Daiichi Sankyo cue up TROP2 drug filing in breast cancer

Cancer Research UK earmarks £123m for Scottish R&D

Menarini brings oral SERD to Europe with Orserdu okay

Roche inks pipeline deals with Orionis, PeptiDream

Merck puts $1.3bn into AI via Exscientia, BenevolentAI deals

Novartis returns PD-1 antibody rights to BeiGene

Dexcom is first to join FDA/CMS health tech pilot

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks